Evidence map›Paper›PMID 29526960›Full record

ArticleInternal medicine (Tokyo, Japan)2018

Saibokuto as a Possible Therapy for Type B Insulin Resistance Syndrome: The Disappearance of Anti-insulin Receptor Antibody and a Marked Amelioration of Glycemic Control by Saibokuto Treatment.

Fumiko Kawasaki, Takatoshi Anno, Maiko Takai, Shintaro Irie, Hideaki Kaneto, Kohei Kaku, Niro Okimoto

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Type B insulin resistance syndrome: a systematic review.Archives of endocrinology and metabolism · 2020
    Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Fumiko KawasakiDepartment of General Internal Medicine 1, Kawasaki Medical School, Japan.
Takatoshi AnnoDepartment of General Internal Medicine 1, Kawasaki Medical School, Japan.
Maiko TakaiDepartment of General Internal Medicine 1, Kawasaki Medical School, Japan.
Shintaro IrieDepartment of General Internal Medicine 1, Kawasaki Medical School, Japan.
Hideaki KanetoDepartment of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Japan.
Kohei KakuDepartment of General Internal Medicine 1, Kawasaki Medical School, Japan.
Niro OkimotoDepartment of General Internal Medicine 1, Kawasaki Medical School, Japan.
Kawasaki Medical School · JPKawasaki Medical School Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type B insulin resistance syndrome is a rare autoimmune disease and no effective therapy has yet been established. On the other hand, it is known that Saibokuto, one type of Japanese Kampo medicine, may have beneficial effects on various symptoms associated with this disease and it is therefore occasionally prescribed for various immune disorders. We herein describe a case of type B insulin resistance syndrome in which anti-insulin receptor antibody disappeared and the patient's glycemic control markedly improved after the administration of Saibokuto. At first, we administered various anti-oral diabetic drugs and insulin therapy, but the patient's glycemic control became further aggravated. In addition, Helicobacter pylori eradication therapy was not effective, although its benefit has been reported. Interestingly, after the patient started taking Saibokuto, her glycemic control markedly improved. In addition, the patient's plasma insulin levels markedly decreased and anti-insulin receptor antibody became negative after taking Saibokuto. Taken together, there is a possibility that Saibokuto may one of the options for type B insulin resistance syndrome therapy.

Indexed as

Insulin ResistanceMedicine, KampoAntibodiesAutoimmune DiseasesBlood GlucoseFemaleHumansInsulinMaleReceptor, InsulinSyndromeAntibodiesBlood GlucoseInsulinReceptor, Insulinsaiboku-toanti-insulin receptor antibodySaibokutotype B insulin resistance syndrome

Identifiers

PMID29526960
PMCPMC6148171
OpenAlexW2792255324

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.